Drug Trial Radar · NCT07861425
Phase 1 Trial of ACE723, A Dual-Payload Antibody Drug Conjugate, in Patients With Advanced HCC Who Have Failed or Progressed on Standard Systemic Therapy Containing ICIs
Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
70
Planned (sponsor's estimate)
Start
Nov 2026
Primary completion
May 2030
Study completion May 2030
Sponsor
- Lead sponsor
- Acepodia Biotech, Inc.Industry
- Sponsor type
- Industry
- First posted
- Oct 6, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
ACE723 is a dual-payload antibody drug conjugate targeting glypican-3 (GPC-3) that is under investigation for the treatment of unresectable or metastatic hepatocellular carcinoma (HCC).
Conditions
- Hepatocellular Carcinoma (HCC)
- Hepatocellular Carcinoma Metastatic
- Hepatocellular Carcinoma Non-Resectable
Interventions
ACE723Drug
Intravenous Administration
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1: To assess the safety and tolerability of ACE723 administered at multiple ascending dosesTime frame: Up to 12 months post-last dose
- Part 1: To determine the maximum tolerated dose (MTD) of ACE723Time frame: Up to 12 months post-last dose
- Part 1: To determine the recommended ACE723 doses for further evaluation in the dose expansion phaseTime frame: Up to 12 months post-last dose
- Part 2: To assess the safety and tolerability of ACE723 at the expansion dosesTime frame: Up to 12 months post-last dose
- Part 2: To determine the Recommended Phase 2 Dose (RP2D) of ACE723 for further clinical evaluationTime frame: Up to 12 months post-last dose
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Nanjing Tianyinshan Hospital
Nanjing, China · Recruiting
Zhongshan Hospital, Fudan University
Shanghai, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.